Kessler Topaz Meltzer & Check, LLP - Class Action Announcement for Ultragenyx Pharmaceutical Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Ultragenyx Pharmaceutical Inc.
Ultragenyx PharmaceuticalUltragenyx Pharmaceutical(US:RARE) Globenewswire·2026-02-16 16:15

Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to seek lead plaintiff status: April 6, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s drug, setrusumabInvestor action: Contact Kessler Topaz Meltzer & Check, LLP (www. ...